Chiron Pulminiq Gets Pulmonary-Allergy Committee Review June 6
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee review of the immunosuppressant will likely focus on FDA-requested analysis of pivotal data for the lung transplant treatment. Chiron confirms that FDA extended Pulminiq's user fee action date by 90 days, to July 15.